688606 奥泰生物
交易中 03-24 14:51:14
资讯
新帖
简况
奥泰生物（688606）披露股份回购进展公告，3月23日股价下跌3.01%
证券之星 · 03-23 22:54
奥泰生物（688606）披露股份回购进展公告，3月23日股价下跌3.01%
每周股票复盘：奥泰生物（688606）回购股份达1.03%支付超5450万元
证券之星 · 03-22 03:28
每周股票复盘：奥泰生物（688606）回购股份达1.03%支付超5450万元
奥泰生物（688606）披露以集中竞价交易方式回购公司股份比例达到1%暨回购进展公告，3月18日股价上涨1.57%
证券之星 · 03-18
奥泰生物（688606）披露以集中竞价交易方式回购公司股份比例达到1%暨回购进展公告，3月18日股价上涨1.57%
奥泰生物新注册《多通道荧光免疫分析仪软件V1.0.0》等4个项目的软件著作权
证券之星 · 02-12
奥泰生物新注册《多通道荧光免疫分析仪软件V1.0.0》等4个项目的软件著作权
每周股票复盘：奥泰生物（688606）披露回购股份事项股东持股情况
证券之星 · 02-08
每周股票复盘：奥泰生物（688606）披露回购股份事项股东持股情况
奥泰生物（688606）披露回购股份事项前十名股东持股情况，2月3日股价上涨2.23%
证券之星 · 02-03
奥泰生物（688606）披露回购股份事项前十名股东持股情况，2月3日股价上涨2.23%
每周股票复盘：奥泰生物（688606）披露回购股份股东持股情况
证券之星 · 02-01
每周股票复盘：奥泰生物（688606）披露回购股份股东持股情况
每周股票复盘：奥泰生物（688606）拟回购股份金额不低于1亿元
证券之星 · 01-25
每周股票复盘：奥泰生物（688606）拟回购股份金额不低于1亿元
奥泰生物（688606）披露2026年第一次临时股东会会议资料，1月23日股价上涨1.52%
证券之星 · 01-23
奥泰生物（688606）披露2026年第一次临时股东会会议资料，1月23日股价上涨1.52%
奥泰生物最新公告：拟以1亿元-2亿元回购公司股份
证券之星 · 01-21
奥泰生物最新公告：拟以1亿元-2亿元回购公司股份
奥泰生物最新公告：控股股东、实际控制人、董事长提议公司回购股份
证券之星 · 01-19
奥泰生物最新公告：控股股东、实际控制人、董事长提议公司回购股份
奥泰生物（688606）披露2024年限制性股票激励计划首次授予第一个归属期归属结果，12月12日股价上涨1.81%
证券之星 · 2025-12-12
奥泰生物（688606）披露2024年限制性股票激励计划首次授予第一个归属期归属结果，12月12日股价上涨1.81%
奥泰生物（688606）披露取消监事会并修订公司章程议案获通过，11月25日股价上涨0.95%
证券之星 · 2025-11-25
奥泰生物（688606）披露取消监事会并修订公司章程议案获通过，11月25日股价上涨0.95%
每周股票复盘：奥泰生物（688606）拟取消监事会
证券之星 · 2025-11-16
每周股票复盘：奥泰生物（688606）拟取消监事会
奥泰生物（688606）披露拟取消监事会并修订公司章程，11月13日股价上涨0.51%
证券之星 · 2025-11-13
奥泰生物（688606）披露拟取消监事会并修订公司章程，11月13日股价上涨0.51%
奥泰生物、奥浦迈生物、恒瑞医药高管同台探讨：中国何时诞生世界级医药企业？
新浪证券 · 2025-11-13
奥泰生物、奥浦迈生物、恒瑞医药高管同台探讨：中国何时诞生世界级医药企业？
奥泰生物高飞：AI能否真正提升药物筛选和研发效率，还需要时间和实践去检验
新浪证券 · 2025-11-13
奥泰生物高飞：AI能否真正提升药物筛选和研发效率，还需要时间和实践去检验
每周股票复盘：奥泰生物（688606）Q3净利降21.52%
证券之星 · 2025-11-02
每周股票复盘：奥泰生物（688606）Q3净利降21.52%
奥泰生物（688606）披露2025年第三季度报告，10月31日股价上涨0.85%
证券之星 · 2025-10-31
奥泰生物（688606）披露2025年第三季度报告，10月31日股价上涨0.85%
图解奥泰生物三季报：第三季度单季净利润同比下降21.52%
证券之星 · 2025-10-30
图解奥泰生物三季报：第三季度单季净利润同比下降21.52%
加载更多
公司概况
公司名称：
杭州奥泰生物技术股份有限公司
所属行业：
医药制造业
上市日期：
2021-03-25
主营业务：
杭州奥泰生物技术股份有限公司的主营业务是体外快速诊断试剂的研发、生产和销售。公司的主要产品是传染病类、毒品及药物滥用类、妇女健康类、新冠检测类、肿瘤类、心肌类。报告期内，公司新增授权专利/软件著作权共23项；新增国内外医疗器械产品认证203项。截至报告期末，公司已累计获得专利/软件著作权219项，累计已取得国内外医疗器械备案以及产品注册证书3058项。
发行价格：
133.67
{"stockData":{"symbol":"688606","market":"SH","secType":"STK","nameCN":"奥泰生物","latestPrice":63.02,"timestamp":1774335074000,"preClose":62.56,"halted":0,"volume":238572,"delay":0,"changeRate":0.0074,"floatShares":79280900,"shares":79280900,"eps":3.7179,"marketStatus":"交易中","change":0.46,"latestTime":"03-24 14:51:14","open":62.98,"high":63.86,"low":62.52,"amount":15018000,"amplitude":0.0214,"askPrice":63.08,"askSize":6,"bidPrice":63.02,"bidSize":1,"shortable":0,"etf":0,"ttmEps":3.7179,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1774335600000},"marketStatusCode":2,"adr":0,"adjPreClose":62.56,"symbolType":"stock_kcb","openAndCloseTimeList":[[1774315800000,1774323000000],[1774328400000,1774335600000]],"highLimit":68.82,"lowLimit":56.3,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":79280855,"isCdr":false,"pbRate":1.27,"roa":"--","peRate":16.950429,"roe":"4.85%","epsLYR":3.82,"committee":-0.357143,"marketValue":4996000000,"turnoverRate":0.003,"status":0,"floatMarketCap":4996000000},"requestUrl":"/m/hq/s/688606","defaultTab":"news","newsList":[{"id":"2621707881","title":"奥泰生物（688606）披露股份回购进展公告，3月23日股价下跌3.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621707881","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621707881?lang=zh_cn&edition=full","pubTime":"2026-03-23 22:54","pubTimestamp":1774277658,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，奥泰生物报收于62.56元，较前一交易日下跌3.01%，最新总市值为49.6亿元。该股当日开盘64.15元，最高65.0元，最低62.4元，成交额达2875.29万元，换手率为0.57%。近日，杭州奥泰生物技术股份有限公司发布关于股份回购进展公告。公告显示，公司于2026年1月22日披露股份回购方案，回购期限为2026年2月9日至2027年2月8日，预计回购金额为10,000万元至20,000万元，回购股份用于减少注册资本。本次回购符合相关法规及公司方案规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300040343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2621979181","title":"每周股票复盘：奥泰生物（688606）回购股份达1.03%支付超5450万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621979181","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621979181?lang=zh_cn&edition=full","pubTime":"2026-03-22 03:28","pubTimestamp":1774121292,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，奥泰生物报收于64.5元，较上周的66.18元下跌2.54%。本周，奥泰生物3月16日盘中最高价报67.2元。奥泰生物当前最新总市值51.14亿元，在医疗器械板块市值排名66/129，在两市A股市值排名3323/5190。本周关注点公司公告汇总：回购股份比例已达1.03%，支付资金总额54,509,397.69元公司公告汇总杭州奥泰生物技术股份有限公司于2026年1月22日披露回购方案，拟以超募资金通过集中竞价交易方式回购股份，用于减少注册资本。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200001333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2620257348","title":"奥泰生物（688606）披露以集中竞价交易方式回购公司股份比例达到1%暨回购进展公告，3月18日股价上涨1.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620257348","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620257348?lang=zh_cn&edition=full","pubTime":"2026-03-18 22:44","pubTimestamp":1773845054,"startTime":"0","endTime":"0","summary":"截至2026年3月18日收盘，奥泰生物报收于66.55元，较前一交易日上涨1.57%，最新总市值为52.76亿元。该股当日开盘65.52元，最高66.64元，最低65.25元，成交额达1653.17万元，换手率为0.32%。近日，杭州奥泰生物技术股份有限公司发布《关于以集中竞价交易方式回购公司股份比例达到1%暨回购进展公告》。公告显示，公司于2026年1月22日披露回购方案，拟以超募资金通过集中竞价交易方式回购股份，用于减少注册资本。本次回购符合相关法规及公司方案规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800040966.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2610950946","title":"奥泰生物新注册《多通道荧光免疫分析仪软件V1.0.0》等4个项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2610950946","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610950946?lang=zh_cn&edition=full","pubTime":"2026-02-12 02:01","pubTimestamp":1770832882,"startTime":"0","endTime":"0","summary":"证券之星消息，近日奥泰生物新注册了4个项目的软件著作权，包括《多通道荧光免疫分析仪软件V1.0.0》、《便携式荧光免疫分析仪软件V1.0.0》、《尿联分析仪上位机软件V1.0.0》、《动物荧光免疫分析仪软件V1.0.0》等。今年以来奥泰生物新注册软件著作权4个。通过天眼查大数据分析，杭州奥泰生物技术股份有限公司共对外投资了7家企业，参与招投标项目163次；财产线索方面有商标信息344条，专利信息213条，著作权信息9条；此外企业还拥有行政许可538个。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200001327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2609482526","title":"每周股票复盘：奥泰生物（688606）披露回购股份事项股东持股情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2609482526","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609482526?lang=zh_cn&edition=full","pubTime":"2026-02-08 03:11","pubTimestamp":1770491470,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，奥泰生物报收于68.84元，较上周的69.41元下跌0.82%。本周，奥泰生物2月4日盘中最高价报69.75元。本周关注点公司公告汇总：奥泰生物披露截至2026年2月2日回购股份事项前十名股东持股情况。公司股份全部为无限售条件流通股，前十名股东与前十名无限售条件股东持股情况一致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800001147.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2608821268","title":"奥泰生物（688606）披露回购股份事项前十名股东持股情况，2月3日股价上涨2.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608821268","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608821268?lang=zh_cn&edition=full","pubTime":"2026-02-03 17:48","pubTimestamp":1770112106,"startTime":"0","endTime":"0","summary":"截至2026年2月3日收盘，奥泰生物报收于69.22元，较前一交易日上涨2.23%，最新总市值为54.88亿元。该股当日开盘68.04元，最高69.35元，最低68.01元，成交额达2938.63万元，换手率为0.54%。近日，奥泰生物发布《关于回购股份事项前十名股东和前十名无限售条件股东持股情况的公告》。现披露截至2026年第一次临时股东会股权登记日登记在册的前十名股东和前十名无限售条件股东的持股情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300030904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2608829070","title":"每周股票复盘：奥泰生物（688606）披露回购股份股东持股情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2608829070","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608829070?lang=zh_cn&edition=full","pubTime":"2026-02-01 03:46","pubTimestamp":1769888770,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，奥泰生物报收于69.41元，较上周的70.6元下跌1.69%。本周，奥泰生物1月26日盘中最高价报72.88元。本周关注点公司公告汇总：奥泰生物披露回购方案前一交易日前十名股东持股情况。公司公告汇总关于回购股份事项前十名股东和前十名无限售条件股东持股情况的公告杭州奥泰生物技术股份有限公司于2026年1月21日召开董事会，审议通过以集中竞价交易方式回购公司股份的方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2606423755","title":"每周股票复盘：奥泰生物（688606）拟回购股份金额不低于1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606423755","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606423755?lang=zh_cn&edition=full","pubTime":"2026-01-25 03:30","pubTimestamp":1769283031,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，奥泰生物报收于70.6元，较上周的65.43元上涨7.9%。本周关注点公司公告汇总：控股股东提议以超募资金回购股份，金额不低于1亿元且不超过2亿元。回购资金总额不低于1亿元且不超过2亿元，价格不超过董事会决议前30个交易日股票交易均价的150%，回购期限为股东会审议通过之日起12个月内。回购股份将全部用于减少注册资本。其中，回购股份议案为特别决议议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500001253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2605092734","title":"奥泰生物（688606）披露2026年第一次临时股东会会议资料，1月23日股价上涨1.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605092734","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605092734?lang=zh_cn&edition=full","pubTime":"2026-01-23 23:14","pubTimestamp":1769181257,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，奥泰生物报收于70.6元，较前一交易日上涨1.52%，最新总市值为55.97亿元。该股当日开盘69.96元，最高70.79元，最低68.62元，成交额达7124.46万元，换手率为1.29%。其中，回购股份议案为特别决议议案，需经出席会议股东所持表决权的三分之二以上通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300043924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2605704831","title":"奥泰生物最新公告：拟以1亿元-2亿元回购公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2605704831","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605704831?lang=zh_cn&edition=full","pubTime":"2026-01-21 17:41","pubTimestamp":1768988476,"startTime":"0","endTime":"0","summary":"奥泰生物(688606.SH)公告称，公司拟以不低于人民币1亿元（含），不超过人民币2亿元（含）的首次公开发行股票超募资金，通过集中竞价交易方式回购公司已发行的部分人民币普通股（A股）股票，并将回购股份全部用于注销即减少注册资本。回购股份价格不超过人民币85元/股（含）。回购期限为自股东会审议通过最终股份回购方案之日起不超过12个月。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100029668.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2604187538","title":"奥泰生物最新公告：控股股东、实际控制人、董事长提议公司回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2604187538","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604187538?lang=zh_cn&edition=full","pubTime":"2026-01-19 18:10","pubTimestamp":1768817403,"startTime":"0","endTime":"0","summary":"奥泰生物(688606.SH)公告称，公司于2026年1月16日收到控股股东、实际控制人、董事长高飞《关于提议杭州奥泰生物技术股份有限公司回购公司股份的函》。提议内容为：以首次公开发行股票超募资金通过集中竞价交易方式回购公司股份，回购股份全部用于注销即减少注册资本，资金总额不低于人民币10,000万元（含），不超过人民币20,000万元（含）。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900025408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2590502609","title":"奥泰生物（688606）披露2024年限制性股票激励计划首次授予第一个归属期归属结果，12月12日股价上涨1.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590502609","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590502609?lang=zh_cn&edition=full","pubTime":"2025-12-12 22:31","pubTimestamp":1765549872,"startTime":"0","endTime":"0","summary":"截至2025年12月12日收盘，奥泰生物报收于62.93元，较前一交易日上涨1.81%，最新总市值为49.89亿元。近日，奥泰生物发布关于2024年限制性股票激励计划首次授予第一个归属期归属结果的公告。公告显示，公司已完成2024年限制性股票激励计划首次授予第一个归属期的股份登记，本次归属股票数量为381,100股，来源为公司从二级市场回购的A股普通股股票，归属人数为54人。经审验，公司已收到激励对象认缴股款9,646,250.76元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200042029.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2586719664","title":"奥泰生物（688606）披露取消监事会并修订公司章程议案获通过，11月25日股价上涨0.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586719664","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586719664?lang=zh_cn&edition=full","pubTime":"2025-11-25 22:36","pubTimestamp":1764081362,"startTime":"0","endTime":"0","summary":"截至2025年11月25日收盘，奥泰生物报收于66.69元，较前一交易日上涨0.95%，最新总市值为52.87亿元。该股当日开盘65.82元，最高67.02元，最低65.82元，成交额达1369.42万元，换手率为0.26%。根据近日发布的公告，杭州奥泰生物技术股份有限公司于2025年11月25日召开2025年第二次临时股东大会，审议通过了《关于取消监事会、修订<公司章程>并办理工商变更登记的议案》。该议案为特别决议议案，获得出席股东所持表决权三分之二以上通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500039772.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2583548976","title":"每周股票复盘：奥泰生物（688606）拟取消监事会","url":"https://stock-news.laohu8.com/highlight/detail?id=2583548976","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583548976?lang=zh_cn&edition=full","pubTime":"2025-11-16 04:19","pubTimestamp":1763237949,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，奥泰生物报收于70.55元，较上周的67.96元上涨3.81%。本周，奥泰生物11月14日盘中最高价报71.45元。11月10日盘中最低价报67.7元。奥泰生物当前最新总市值55.93亿元，在医疗器械板块市值排名68/126，在两市A股市值排名3105/5165。同时，增选陈善基为第三届董事会独立董事。相关议案已提交第三届董事会第十七次会议审议通过，并提请2025年第二次临时股东大会审议。会议采取现场与网络投票相结合方式，于2025年11月25日召开。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2583591818","title":"奥泰生物（688606）披露拟取消监事会并修订公司章程，11月13日股价上涨0.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583591818","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583591818?lang=zh_cn&edition=full","pubTime":"2025-11-13 22:50","pubTimestamp":1763045430,"startTime":"0","endTime":"0","summary":"截至2025年11月13日收盘，奥泰生物报收于70.45元，较前一交易日上涨0.51%，最新总市值为55.85亿元。该股当日开盘69.99元，最高70.68元，最低69.22元，成交额达3823.94万元，换手率为0.69%。近日，奥泰生物发布《2025年第二次临时股东大会会议资料》公告，宣布拟取消公司监事会，由董事会审计委员会行使监事会职权，并对《公司章程》及相关内部管理制度进行修订。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300042764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2583562646","title":"奥泰生物、奥浦迈生物、恒瑞医药高管同台探讨：中国何时诞生世界级医药企业？","url":"https://stock-news.laohu8.com/highlight/detail?id=2583562646","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583562646?lang=zh_cn&edition=full","pubTime":"2025-11-13 20:07","pubTimestamp":1763035620,"startTime":"0","endTime":"0","summary":" 11月13日，在上海证券交易所国际投资者大会的圆桌论坛上，嘉宾们围绕“中国能否诞生世界级的医药企业？” 杭州奥泰生物技术股份有限公司董事长、总经理高飞表示，世界级企业在中国“肯定会出现”。他表示，生物医药企业要在全球产生价值，必须先在中国市场形成价值基础，而国家在政策端的持续支持至关重要。 现场讨论认为，随着创新能力提升、政策不断完善，中国医药产业未来有望孕育世界级的一流企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-11-13/doc-infxhkcu5227361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0196","LU2097828805.USD","LU2580892789.USD","BK0012","LU1997245177.USD","LU2328871848.SGD","LU2097828557.USD","LU1064131003.USD","LU1997245094.SGD","LU0405327494.USD","LU2289578879.USD","LU1328615791.USD","LU2097828631.EUR","688606","BK0060","LU2580892862.HKD","01276","LU0405327148.USD","LU0359201612.USD","LU1064130708.USD","600276","LU0359202008.SGD","LU1655091616.SGD","LU1997244956.HKD","LU1969619763.USD","BK0239","LU2097828714.EUR","BK0028","LU2148510915.USD","BK0216","BK0188","688293","BK1191","LU1781817850.SGD","LU0359201885.HKD","LU1023057109.AUD","LU2097828474.EUR","LU1255011170.USD","LU1146622755.USD","LU2543165471.USD","LU2495084118.USD","LU1580142542.USD","BK0183","LU2488822045.USD","LU1820825898.SGD"],"gpt_icon":0},{"id":"2583369345","title":"奥泰生物高飞：AI能否真正提升药物筛选和研发效率，还需要时间和实践去检验","url":"https://stock-news.laohu8.com/highlight/detail?id=2583369345","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583369345?lang=zh_cn&edition=full","pubTime":"2025-11-13 10:58","pubTimestamp":1763002680,"startTime":"0","endTime":"0","summary":" 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 高飞指出，医疗器械行业与创新药存在显著差异。 在谈及AI与医药行业的结合时，高飞表示，AI的热潮虽推动了创新药研发与医疗数据分析，但其在实际落地中仍需长期验证。“AI能否真正提升药物筛选和研发效率，还需要时间和实践去检验。”","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-11-13/doc-infxfnye5570602.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2580405630","title":"每周股票复盘：奥泰生物（688606）Q3净利降21.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580405630","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580405630?lang=zh_cn&edition=full","pubTime":"2025-11-02 10:23","pubTimestamp":1762050189,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，奥泰生物报收于68.8元，较上周的68.85元下跌0.07%。本周，奥泰生物10月28日盘中最高价报69.96元。奥泰生物当前最新总市值54.55亿元，在医疗器械板块市值排名65/126，在两市A股市值排名3085/5163。股本股东变化截至2025年9月30日，奥泰生物股东户数为5739户，较6月30日减少131户，减幅2.23%。业绩披露要点奥泰生物2025年三季报显示，前三季度主营收入6.33亿元，同比上升2.44%；归母净利润1.9亿元，同比下降3.91%；扣非净利润1.47亿元，同比下降4.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200002378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2579505754","title":"奥泰生物（688606）披露2025年第三季度报告，10月31日股价上涨0.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579505754","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579505754?lang=zh_cn&edition=full","pubTime":"2025-10-31 18:32","pubTimestamp":1761906765,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，奥泰生物报收于68.8元，较前一交易日上涨0.85%，最新总市值为54.55亿元。近日，奥泰生物发布《2025年第三季度报告》，披露了公司前三季度主要财务数据。截至2025年9月30日，公司总资产为4,242,026,338.42元，较上年度末增长1.34%；归属于上市公司股东的所有者权益为3,901,773,832.63元，较上年度末增长0.47%。公告指出，高飞与赵华芳通过一致行动协议合计控制公司52.76%的股份，为公司实际控制人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100040055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2579143659","title":"图解奥泰生物三季报：第三季度单季净利润同比下降21.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579143659","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579143659?lang=zh_cn&edition=full","pubTime":"2025-10-30 19:37","pubTimestamp":1761824262,"startTime":"0","endTime":"0","summary":"证券之星消息，奥泰生物2025年三季报显示，前三季度公司主营收入6.33亿元，同比上升2.44%；归母净利润1.9亿元，同比下降3.91%；扣非净利润1.47亿元，同比下降4.7%；其中2025年第三季度，公司单季度主营收入2.03亿元，同比下降8.26%；单季度归母净利润5779.7万元，同比下降21.52%；单季度扣非净利润3763.32万元，同比下降38.31%；负债率8.03%，投资收益883.17万元，财务费用-1237.33万元，毛利率56.21%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000040203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774335083366,"stockEarnings":[{"period":"1week","weight":-0.06},{"period":"1month","weight":-0.0838},{"period":"3month","weight":-0.0056},{"period":"6month","weight":-0.0583},{"period":"1year","weight":-0.1003},{"period":"ytd","weight":-0.0208}],"compareEarnings":[{"period":"1week","weight":-0.0665},{"period":"1month","weight":-0.0658},{"period":"3month","weight":-0.0272},{"period":"6month","weight":-0.0105},{"period":"1year","weight":0.1333},{"period":"ytd","weight":-0.0392}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"杭州奥泰生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"5665人(较上一季度减少1.29%)","perCapita":"13994股","listingDate":"2021-03-25","address":"浙江省杭州市钱塘区经济技术开发区白杨街道银海街550号第3幢第4幢第5幢厂房","registeredCapital":"7928万元","survey":" 杭州奥泰生物技术股份有限公司的主营业务是体外快速诊断试剂的研发、生产和销售。公司的主要产品是传染病类、毒品及药物滥用类、妇女健康类、新冠检测类、肿瘤类、心肌类。报告期内，公司新增授权专利/软件著作权共23项；新增国内外医疗器械产品认证203项。截至报告期末，公司已累计获得专利/软件著作权219项，累计已取得国内外医疗器械备案以及产品注册证书3058项。","listedPrice":133.67},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥泰生物(688606)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥泰生物(688606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥泰生物,688606,奥泰生物股票,奥泰生物股票老虎,奥泰生物股票老虎国际,奥泰生物行情,奥泰生物股票行情,奥泰生物股价,奥泰生物股市,奥泰生物股票价格,奥泰生物股票交易,奥泰生物股票购买,奥泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥泰生物(688606)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥泰生物(688606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}